Jennifer L. Caswell-Jin

发表

Using natural language processing to construct a metastatic breast cancer cohort from linked cancer registry and electronic medical records data pdf

Nigam H. Shah, George W. Sledge, Allison W. Kurian, 2019, JAMIA open.

Dynamics of breast cancer relapse reveal late recurring ER-positive genomic subgroups

Bin Liu, José Antonio Seoane Fernández, Carlos Caldas, 2019, Nature.

Patient perspectives on window of opportunity clinical trials in early-stage breast cancer

Jennifer L. Caswell-Jin, G. Sledge, C. Curtis, 2022, Breast Cancer Research and Treatment.

Chromatin Regulators Mediate Anthracycline Sensitivity in Breast Cancer

Jennifer L. Caswell-Jin, G. Crabtree, C. Curtis, 2019, Nature Medicine.

Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast

Jennifer L. Caswell-Jin, K. Jones, Yunni-Yi Chen, 2022, Modern Pathology.

Chemotherapy Regimens Received by Women With BRCA1/2 Pathogenic Variants for Early Stage Breast Cancer Treatment

Jennifer L. Caswell-Jin, S. Gomez, K. Ward, 2022, JNCI cancer spectrum.

Breast cancer diagnosis and treatment during the COVID-19 pandemic in a nationwide, insured population

Jennifer L. Caswell-Jin, E. John, M. Bondy, 2022, Breast Cancer Research and Treatment.

Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response

Jennifer L. Caswell-Jin, C. Curtis, J. Beechem, 2020, Nature Cancer.

Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy

Johannes G. Reiter, Jennifer L. Caswell-Jin, R. West, 2019, Nature Communications.

Natural Language Processing Approaches to Detect the Timeline of Metastatic Recurrence of Breast Cancer.

Selen Bozkurt, Imon Banerjee, Daniel L Rubin, 2019, JCO clinical cancer informatics.

Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk

James M Ford, Jennifer L. Caswell-Jin, Allison W Kurian, 2017, Genetics in Medicine.

Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative

Anjali D. Zimmer, Jennifer L. Caswell-Jin, Will Stedden, 2018, Journal of the National Cancer Institute.

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

Jennifer L. Caswell-Jin, A. Giuliano, C. Curtis, 2020, Nature Communications.

Prevalence of Pathogenic Variants in Cancer Susceptibility Genes Among Women With Postmenopausal Breast Cancer.

Jennifer L. Caswell-Jin, A. Kurian, M. Stefanick, 2020, JAMA.

Response to Peshkin, Isaacs, and Schwartz.

Jennifer L. Caswell-Jin, A. Kurian, 2019, Journal of the National Cancer Institute.

Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing?

Jennifer L. Caswell-Jin, A. Kurian, M. Mills, 2018, JCO precision oncology.

Performance of the IBIS/Tyrer‐Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative

Jennifer L. Caswell-Jin, J. Manson, E. John, 2021, Cancer.

Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review

Jennifer L. Caswell-Jin, S. Plevritis, L. Tian, 2018, JNCI cancer spectrum.

Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer

Jennifer L. Caswell-Jin, N. Myall, J. Neal, 2023, JACC. CardioOncology.

Androgen receptor agonists as breast cancer therapeutics

Jennifer L. Caswell-Jin, C. Curtis, 2021, Nature Medicine.

Genome-wide association study identiﬁes variants at 16p13 associated with survival in multiple myeloma patients

Jennifer L. Caswell-Jin, E. Ziv, N. Camp, 2022 .

Treatment and Monitoring Variability in US Metastatic Breast Cancer Care.

Jennifer L. Caswell-Jin, Summer S. Han, N. Shah, 2021, JCO clinical cancer informatics.

Patient perspectives on window of opportunity clinical trials in early-stage breast cancer

Jennifer L. Caswell-Jin, G. Sledge, C. Curtis, 2022, Breast Cancer Research and Treatment.

Molecular Heterogeneity and Evolution in Breast Cancer

Jennifer L. Caswell-Jin, C. Curtis, C. Lorenz, 2021 .

Genome-wide association study identifies variants at 16 p 13 associated with survival in multiple myeloma patients

Jennifer L. Caswell-Jin, E. Ziv, N. Camp, 2015 .

First-in-human phase 1/2 dose escalation and expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with solid tumors.

Jennifer L. Caswell-Jin, F. Meric-Bernstam, A. El-Khoueiry, 2022, Journal of Clinical Oncology.

Contributions of screening, early-stage treatment, and metastatic treatment to breast cancer mortality reduction by molecular subtype in U.S. women, 2000-2017.

Jennifer L. Caswell-Jin, D. Berry, S. Plevritis, 2022, Journal of Clinical Oncology.

Performance of the IBIS/Tyrer-Cuzick (TC) Model by race/ethnicity in the Women’s Health Initiative.

Jennifer L. Caswell-Jin, J. Manson, A. Gutin, 2020 .

Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy

Johannes G. Reiter, Jennifer L. Caswell-Jin, R. West, 2019, Nature Communications.

Analysis of Breast Cancer Mortality in the US-1975 to 2019.

Jennifer L. Caswell-Jin, A. Trentham-Dietz, J. Mandelblatt, 2024, JAMA.